Retrophin, Inc.
(NASDAQ : RTRX)

( )
RTRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -4.54%69.361.0%$1437.62m
BIIBBiogen, Inc. -0.55%308.391.5%$631.19m
REGNRegeneron Pharmaceuticals, Inc. 3.00%444.572.6%$540.75m
AMGNAmgen, Inc. -1.85%199.731.3%$516.67m
ILMNIllumina, Inc. 2.21%265.673.5%$404.58m
MRNAModerna, Inc. -0.88%25.930.0%$374.64m
VRTXVertex Pharmaceuticals, Inc. 0.33%224.031.9%$349.56m
ALXNAlexion Pharmaceuticals, Inc. 2.11%94.032.0%$225.36m
CODXCo-Diagnostics, Inc. -17.11%13.230.0%$205.07m
AAgilent Technologies, Inc. -0.59%76.971.6%$168.76m
EXASEXACT Sciences Corp. 0.16%80.9524.0%$163.88m
BMRNBioMarin Pharmaceutical, Inc. 0.61%90.374.3%$115.44m
SGENSeattle Genetics, Inc. 5.12%113.866.1%$111.32m
INCYIncyte Corp. -0.57%75.412.5%$109.76m
NVAXNovavax, Inc. 35.59%16.00184.0%$89.13m

Company Profile

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.